News articles about Endo International (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.4412991230527 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
Endo International stock opened at $5.49 on Monday. The company has a current ratio of 1.02, a quick ratio of 0.85 and a debt-to-equity ratio of 17.00. The stock has a market cap of $1,226.14, a price-to-earnings ratio of 1.43 and a beta of 0.38. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $14.15.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.15. The business had revenue of $768.64 million for the quarter, compared to the consensus estimate of $762.29 million. Endo International had a positive return on equity of 81.03% and a negative net margin of 58.68%. The company’s quarterly revenue was down 38.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.77 EPS. research analysts forecast that Endo International will post 2.33 earnings per share for the current year.
Several research analysts have recently commented on ENDP shares. Mizuho reissued a “buy” rating and issued a $12.00 price target (down from $14.00) on shares of Endo International in a research report on Wednesday, January 3rd. Leerink Swann started coverage on Endo International in a research report on Tuesday, January 2nd. They issued an “outperform” rating and a $12.00 price target for the company. Vetr raised Endo International from a “buy” rating to a “strong-buy” rating and set a $8.92 price target for the company in a research report on Tuesday, December 26th. Zacks Investment Research lowered Endo International from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. Finally, BidaskClub downgraded Endo International from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 31st. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $9.40.
ILLEGAL ACTIVITY NOTICE: “Endo International (ENDP) Receives News Impact Score of 0.06” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/endo-international-endp-receives-news-impact-score-of-0-06.html.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.